[{"data":1,"prerenderedAt":213},["ShallowReactive",2],{"drug-voriconazole":3},{"id":4,"schemaVersion":5,"name":6,"category":9,"class":10,"brands":13,"synonyms":17,"formulations":21,"regimens":36,"contraindications":87,"warnings":104,"renal":105,"monitoring":106,"interactions":107,"review":108,"examples":111,"atc":124,"iran":126,"links":146,"populations":164,"usApproval":208},"voriconazole",1,{"fa":7,"en":8},"وریکونازول (وریدی)","Voriconazole (IV)","anti-infectives",{"fa":11,"en":12},"ضدقارچ تری‌آزول","Triazole antifungal",[14],{"name":15,"market":16},"Vfend","US",[18,19,20],"vfend","وفند","وریکونازول",[22],{"id":23,"form":24,"route":25,"label":26,"concentration":27,"markets":31,"refs":32},"vial-200","powder-for-injection","iv","200 mg vial (reconstitute to 10 mg\u002FmL, dilute to ≤5 mg\u002FmL)",{"amount":28,"unit":29,"perUnit":30},200,"mg","vial",[16],[33],{"source":34,"section":35},"fda-vfend","3",[37,66],{"id":38,"disease":39,"label":40,"population":43,"type":47,"unit":29,"dose":48,"refs":51,"notes":54},"adult","invasive-fungal",{"fa":41,"en":42},"بزرگسال و ۱۵ سال به بالا — نگهدارنده ۴ mg\u002Fkg هر ۱۲ ساعت (پس از بارگذاری)","Adults and ≥15 y — maintenance 4 mg\u002Fkg every 12 h (after loading)",{"minAge":44},{"value":45,"unit":46},15,"year","weightBased",{"perKgPerDose":49,"intervalHours":50},4,12,[52],{"source":34,"section":53},"2.3, Table 1",[55],{"text":56,"refs":59},{"fa":57,"en":58},"بارگذاری: ۶ mg\u002Fkg هر ۱۲ ساعت در ۲۴ ساعت اول. کاندیدمی: ۳ تا ۴ mg\u002Fkg. حداقل ۷ روز وریدی، سپس خوراکی ۲۰۰ mg هر ۱۲ ساعت (زیر ۴۰ kg نصف). انفوزیون ۱ تا ۳ ساعت، حداکثر ۳ mg\u002Fkg در ساعت؛ هرگز بولوس. ۱۲ تا ۱۴ سال با وزن ۵۰ kg و بیشتر: دوز بزرگسال.","Loading: 6 mg\u002Fkg every 12 h for the first 24 h. Candidaemia: 3–4 mg\u002Fkg. At least 7 days IV, then oral 200 mg every 12 h (half if \u003C40 kg). Infuse over 1–3 h, max 3 mg\u002Fkg\u002Fh; never as a bolus. 12–14 y weighing ≥50 kg: adult dose.",[60,62,64],{"source":34,"section":61},"2.3",{"source":34,"section":63},"2.1",{"source":34,"section":65},"2.4",{"id":67,"disease":39,"label":68,"population":71,"type":47,"unit":29,"dose":75,"refs":77,"notes":80},"child",{"fa":69,"en":70},"کودک ۲ تا کمتر از ۱۲ سال — نگهدارنده ۸ mg\u002Fkg هر ۱۲ ساعت (پس از بارگذاری)","Child 2 to \u003C12 y — maintenance 8 mg\u002Fkg every 12 h (after loading)",{"minAge":72,"maxAge":74},{"value":73,"unit":46},2,{"value":50,"unit":46},{"perKgPerDose":76,"intervalHours":50},8,[78],{"source":34,"section":79},"2.4, Table 2",[81],{"text":82,"refs":85},{"fa":83,"en":84},"بارگذاری: ۹ mg\u002Fkg هر ۱۲ ساعت در ۲۴ ساعت اول. همین دوز برای ۱۲ تا ۱۴ سال زیر ۵۰ kg. خوراکی: ۹ mg\u002Fkg هر ۱۲ ساعت (حداکثر ۳۵۰ mg).","Loading: 9 mg\u002Fkg every 12 h for the first 24 h. Same dose for 12–14 y under 50 kg. Oral: 9 mg\u002Fkg every 12 h (max 350 mg).",[86],{"source":34,"section":65},[88,97],{"id":89,"severity":90,"text":91,"refs":94},"hyper","block",{"fa":92,"en":93},"حساسیت به وریکونازول.","Hypersensitivity to voriconazole.",[95],{"source":34,"section":96},"4",{"id":98,"severity":90,"text":99,"refs":102},"cyp",{"fa":100,"en":101},"همراه با داروهای وابسته به CYP3A4 با عوارض خطرناک (مثل اپلرنون، ارگوت‌ها، ایوابرادین، لورازیدون، پیموزاید، کینیدین، سیرولیموس، تولواپتان) و القاکننده‌ها (کاربامازپین، باربیتورات طولانی‌اثر، ریفابوتین، ریفامپین، ریتوناویر دوز بالا، علف چای).","With CYP3A4-dependent drugs causing serious reactions (e.g. eplerenone, ergot alkaloids, ivabradine, lurasidone, pimozide, quinidine, sirolimus, tolvaptan) and inducers (carbamazepine, long-acting barbiturates, rifabutin, rifampin, high-dose ritonavir, St John’s wort).",[103],{"source":34,"section":96},[],[],[],[],{"status":109,"reviewer":110,"date":110},"unverified",null,[112,118],{"regimen":38,"formulation":23,"input":113,"expect":116},{"ageYears":114,"weightKg":115},40,70,{"perDose":117},280,{"regimen":67,"formulation":23,"input":119,"expect":122},{"ageYears":120,"weightKg":121},6,20,{"perDose":123},160,[125],"J02AC03",{"status":127,"forms":128,"refs":141},"registered",[129,133,137],{"code":130,"en":131,"fa":132},"06382","VORICONAZOLE 200MG TAB","قرص ووریکونازول ۲۰۰ میلی‌گرم",{"code":134,"en":135,"fa":136},"06383","VORICONAZOLE 200MG VIAL","ویال ووریکونازول ۲۰۰ میلی‌گرم",{"code":138,"en":139,"fa":140},"09604","VORICONAZOLE 50MG TAB","قرص ووریکونازول ۵۰ میلی‌گرم",[142],{"source":143,"section":144,"url":145},"darooyab-generic","G-753\u002FVoriconazole","https:\u002F\u002Fwww.darooyab.ir\u002FG-753\u002FVoriconazole",[147,151,155,159,162],{"kind":148,"url":149,"label":150},"fda","https:\u002F\u002Fwww.accessdata.fda.gov\u002Fscripts\u002Fcder\u002Fdaf\u002Findex.cfm?event=overview.process&ApplNo=021267","NDA021267",{"kind":152,"url":153,"label":154},"dailymed","https:\u002F\u002Fdailymed.nlm.nih.gov\u002Fdailymed\u002FdrugInfo.cfm?setid=08d08721-1f4c-478a-8abf-d9c402d50553","FDA Vfend IV",{"kind":156,"url":157,"label":158},"medlineplus","https:\u002F\u002Fmedlineplus.gov\u002Fdruginfo\u002Fmeds\u002Fa605022.html","Voriconazole",{"kind":160,"url":161,"label":125},"who-atc","https:\u002F\u002Fatcddd.fhi.no\u002Fatc_ddd_index\u002F?code=J02AC03",{"kind":163,"url":145,"label":158},"darooyab",{"pregnancy":165,"lactation":174,"pediatric":183,"geriatric":191,"reproductive":200},{"level":166,"text":167,"quote":170,"refs":171},"avoid",{"fa":168,"en":169},"برچسب: می‌تواند به جنین آسیب بزند. در بارداری خطرناک است.","Label: can cause fetal harm. Dangerous in pregnancy.","Risk Summary Voriconazole can cause fetal harm when administered to a pregnant woman.",[172],{"source":34,"section":173},"8.1",{"level":175,"text":176,"quote":179,"refs":180},"caution",{"fa":177,"en":178},"برچسب: در شیردهی با احتیاط؛ متن برچسب را ببینید.","Label: use with caution while breastfeeding; see the label text.","Risk Summary No data are available regarding the presence of voriconazole in human milk, the effects of voriconazole on the breastfed infant, or the effects on milk production.",[181],{"source":34,"section":182},"8.2",{"level":175,"text":184,"quote":187,"refs":188},{"fa":185,"en":186},"برچسب برای کودکان شرط، محدودیت سنی یا نکته دارد؛ جمله برچسب در زیر آمده است.","The label has conditions, age limits or notes for children; the label sentence is quoted below.","The safety and effectiveness of VFEND have been established in pediatric patients 2 years of age and older based on evidence from adequate and well-controlled studies in adult and pediatric patients and additional pediatric pharmacokinetic and safety data.",[189],{"source":34,"section":190},"8.4",{"level":192,"text":193,"quote":196,"refs":197},"ok",{"fa":194,"en":195},"برچسب: در سالمندان تفاوت یا تنظیم دوز خاصی ذکر نشده.","Label: no specific difference or dose adjustment stated for older adults.","However, the overall safety profile of the elderly patients was similar to that of the young so no dosage adjustment is recommended [see Clinical Pharmacology (12.3) ] .",[198],{"source":34,"section":199},"8.5",{"level":175,"text":201,"quote":204,"refs":205},{"fa":202,"en":203},"برچسب نکته‌ای درباره بارداری، پیشگیری یا باروری زنان و مردان دارد.","Label has advice on pregnancy testing, contraception or fertility for females and males.","Contraception Advise females of reproductive potential to use effective contraception during treatment with VFEND.",[206],{"source":34,"section":207},"8.3",{"kind":209,"refs":210,"id":150},"NDA",[211],{"source":34,"section":212},"SPL approval \u002F marketing category",1792108440815]